title: Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation.
abstract: A significant proportion of patients with Parkinson's disease (PD) receiving dopamine replacement therapy in the form of levodopa develop dyskinesia that becomes a major complicating factor in treatment. Dyskinesia can only be effectively treated by a reduction in drug dose, which limits efficacy, by co-administration of the weak NMDA antagonist amantadine or by surgical treatment (pallidotomy, DBS). This raises the important question of why dyskinesia occurs in PD and how it can be avoided or suppressed by pharmacological treatment. This review assesses some of the mechanisms that underlie dyskinesia induction and expression from presynaptic changes in dopaminergic neurones to postsynaptic alterations in basal ganglia function and examines potential approaches to prevention and treatment. These include glutamatergic approaches where agents that directly or indirectly alter glutamatergic neurotransmission modify the intracellular influx of Ca(2+) and reduce the formation of nitric oxide by neuronal nitric oxide synthase that may form an integral component of the complex cascade of events leading to dyskinesia. There is increasing evidence for the role of serotoninergic neurones in dyskinesia induction related to non-physiological formation and release of dopamine and serotoninergic agonists can modify dyskinesia expression. Similarly, noradrenergic receptors may serve to alter dyskinesia intensity and α-2-adrenoceptor antagonists alter the expression of levodopa-induced dyskinesia in both experimental models of PD and in man. Finally, other potential approaches to dyskinesia treatment based on manipulation of opiate, cannabinoid, adenosine and histamine receptors are considered. The conclusion is that the cause of levodopa-induced dyskinesia remains to be fully elucidated and that new approaches to treatment through non-dopaminergic mechanisms are required to control the onset and expression of involuntary movements.
authors: Neurodegenerative Disease Research Centre, Institute of Pharmaceutical Sciences, School of Biomedical Sciences, King's College, London, UK. m.iravani@kcl.ac.uk
authors: Mahmoud M
authors: MM
authors: Iravani
authors: Peter
authors: P
authors: Jenner
mesh_terms: D000818:Animals; D000978:Antiparkinson Agents / Q000009:adverse effects*; D059290:Dopaminergic Neurons / Q000187:drug effects / Q000502:physiology; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy / Q000209:etiology* / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D007980:Levodopa / Q000009:adverse effects*; D009473:Neuronal Plasticity / Q000187:drug effects / Q000502:physiology; D018377:Neurotransmitter Agents / Q000378:metabolism / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy; D015398:Signal Transduction / Q000187:drug effects
chemical_list: D000978:Antiparkinson Agents; D018377:Neurotransmitter Agents; D007980:Levodopa